- Home
- LCTX
as 04-25-2025 4:00pm EST
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 95.2M | IPO Year: | N/A |
| Target Price: | $4.20 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.37 - $1.40 | Next Earning Date: | 05-08-2025 |
| Revenue: | $9,499,000 | Revenue Growth: | 6.19% |
| Revenue Growth (this year): | -13.02% | Revenue Growth (next year): | 232.66% |
Stock Insider Trading Activity of Lineage Cell Therapeutics Inc. (LCTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | LCTX | Director10% Owner | Jan 27 '25 | Buy | $0.38 | 7,894,737 | $6,000,000.12 | 49,560,992 |
Latest Lineage Cell Therapeutics Inc. News
LCTX Breaking Stock News: Dive into LCTX Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium
Business Wire
5 days ago
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)
MT Newswires
a month ago
B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating
Thomson Reuters StreetEvents
2 months ago
Q4 2024 Lineage Cell Therapeutics Inc Earnings Call
GuruFocus.com
2 months ago
Lineage Cell Therapeutics Inc (LCTX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...
Zacks
2 months ago
Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates
Business Wire
2 months ago
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Zacks
2 months ago
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Compare LCTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LCTX Lineage Cell Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.